Analyst Reco. Rocket Pharmaceuticals, Inc.

Equities

RCKT

US77313F1066

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
21.98 ^USD	-0.54%		-3.60%	-26.66%

Apr. 16	Rocket Pharmaceuticals Insider Sold Shares Worth $1,945,785, According to a Recent SEC Filing	MT
Apr. 11	Rocket Pharmaceuticals Insider Sold Shares Worth $308,763, According to a Recent SEC Filing	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Rocket Pharmaceuticals Insider Sold Shares Worth $1,945,785, According to a Recent SEC Filing	Apr. 16	MT
Rocket Pharmaceuticals Insider Sold Shares Worth $308,763, According to a Recent SEC Filing	Apr. 11	MT
Goldman Sachs Initiates Rocket Pharmaceuticals at Neutral With $39 Price Target	Apr. 02	MT
UBS Adjusts Rocket Pharmaceuticals Price Target to $54 From $56, Maintains Buy Rating	Mar. 01	MT
Cantor Fitzgerald Initiates Rocket Pharmaceuticals With Overweight Rating, Price Target is $65	23-10-24	MT
Needham Adjusts Rocket Pharmaceuticals' Price Target to $53 From $60, Keeps Buy Rating	23-09-13	MT
Canaccord Genuity Adjusts Price Target on Rocket Pharmaceuticals to $47 From $49, Maintains Buy Rating	23-08-11	MT
Stifel Adjusts Price Target on Rocket Pharmaceuticals to $48 From $53, Keeps Buy Rating	23-08-10	MT
Chardan Adjusts Rocket Pharmaceuticals' Price Target to $61 From $63, Keeps Buy Rating	23-05-08	MT
Raymond James Adjusts Price Target on Rocket Pharmaceuticals to $35 From $33, Maintains Outperform Rating	23-05-05	MT
UBS Adjusts Rocket Pharmaceuticals' Price Target to $56 From $60, Maintains Buy Rating	23-03-15	MT
Chardan Adjusts Price Target on Rocket Pharmaceuticals to $63 From $65, Keeps Buy Rating	23-03-01	MT
Morgan Stanley Initiates Rocket Pharmaceuticals at Overweight With $45 Price Target	23-02-01	MT
SVB Securities Adjusts Price Target on Rocket Pharmaceuticals to $49 From $50, Maintains Outperform Rating	23-01-23	MT
BofA Securities Cuts Price Target on Rocket Pharmaceuticals to $35 From $38, Maintains Buy Rating	22-12-23	MT
SVB Securities Adjusts Rocket Pharmaceuticals' Price Target to $54 From $56, Keeps Outperform Rating	22-12-06	MT
Canaccord Genuity Starts Rocket Pharmaceuticals at Buy With $53 Price Target	22-11-08	MT
UBS Adjusts Rocket Pharmaceuticals Price Target to $60 From $62, Maintains Buy Rating	22-11-07	MT
Raymond James Adjusts Rocket Pharmaceuticals' Price Target to $33 From $34, Keeps Outperform Rating	22-11-07	MT
Needham Adjusts Price Target on Rocket Pharmaceuticals to $60 From $62, Maintains Buy Rating	22-11-04	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Rocket Pharmaceuticals, Inc.

Equities

RCKT

US77313F1066

Analyst Reco.

Filters